Russia Developing Anti-Satellite Capability: White House Responseby Lilu Anderson 16.02.2024Russia is developing "anti-satellite capability," according to the White House, but it is not an immediate threat. The US is ...
StoneX Group Seals $550M Bond Deal for Financial Stabilityby Terry Bingman 16.02.2024Leading financial services organization, StoneX Group, prices $550 million offering of 7.875% Senior Secured Notes due in 2031. Proceeds will ...
Russia’s Space Weapon: No Threat or Secret Menace?by Lilu Anderson 16.02.2024Russia's antisatellite technology poses no immediate threat, according to the White House spokesman. Concerns were raised about a new space-based ...
Hydro One: Stable Financial Results & Growth to 2027by Mark Eisenberg 16.02.2024Hydro One reports strong financial results and outlines growth plans for 2027, including LDC integration and broadband development. The company ...
City National Bank: Linda Duncombe Navigates Financial Stormby Mark Eisenberg 16.02.2024Linda Duncombe, Executive VP of City National Bank, successfully guided clients through industry crises and strikes, providing stability and support.
Uniswap’s Bold Expansion Plan: V2 Across Chainsby John Darbie 13.02.2024Decentralized exchange Uniswap plans to expand by deploying its v2 protocol on multiple blockchains, aiming to recapture liquidity and combat ...
Lumos Boosts Wilmington with $56M Fiber Upgradeby Lilu Anderson 13.02.2024Internet provider Lumos plans to expand fiber optic technology in New Hanover County, bringing high-speed internet and attracting economic growth.
CGI Federal Data Breach Exposes Thousands’ Personal Infoby Lilu Anderson 13.02.2024IT contractor CGI Federal has reported a data breach that exposed personal information of about 6,000 employees, causing potential financial ...
AN2 Therapeutics Pauses Trial: Efficacy Concerns Riseby Mark Eisenberg 12.02.2024AN2 Therapeutics voluntarily pauses enrollment in its epetraborole clinical trial due to lower efficacy. Safety is not a concern. The ...
Atossa Genetics: Potential Breakthrough in Breast Cancer?by Lilu Anderson 12.02.2024Biopharmaceutical company Atossa Genetics receives Buy rating from H.C. Wainwright, with a new price target of $4.00. The company's promising ...